Benzinga · Feb 18, 2026
HI
NASDAQ · HIND
Vyome Holdings, Inc.
Healthcare · Biotechnology
$2.09
Up+$0.06 (+2.96%)
Updated Oct 10, 2026, 11:49 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 27.41M
- P/E ratio
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- $1.75 – $6.56
- Volume
- 7.59K
- Avg. volume
- 321.94K
Price performance · HIND
HIND price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
HIND closed at $2.09 after 21 trading sessions, up 1.46% for the selected period.
- Last close
- $2.09
- Period change
- +1.46%
- Period low
- $1.91
- Period high
- $2.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $2.03 | $2.09 | $2.01 | $2.09 | 7.59K |
| Oct 8, 2026 | $2.03 | $2.0301 | $1.98 | $2.03 | 8K |
| Oct 7, 2026 | $2.02 | $2.06 | $1.98 | $2.04 | 11.37K |
| Oct 6, 2026 | $2.01 | $2.07 | $1.9043 | $2.06 | 13.74K |
| Oct 5, 2026 | $1.9047 | $2.00 | $1.9047 | $1.93 | 10.16K |
| Oct 2, 2026 | $1.84 | $1.96 | $1.82 | $1.91 | 20.22K |
| Oct 1, 2026 | $1.93 | $2.00 | $1.91 | $1.92 | 9K |
| Sep 30, 2026 | $1.93 | $2.0425 | $1.90 | $1.93 | 7.49K |
| Sep 29, 2026 | $1.99 | $2.02 | $1.99 | $2.02 | 8.58K |
| Sep 28, 2026 | $2.01 | $2.06 | $2.01 | $2.03 | 5.14K |
| Sep 25, 2026 | $2.07 | $2.0753 | $2.01 | $2.04 | 9.33K |
| Sep 24, 2026 | $2.0323 | $2.08 | $2.03 | $2.06 | 6.33K |
| Sep 23, 2026 | $1.98 | $2.01 | $1.9472 | $2.01 | 5.46K |
| Sep 22, 2026 | $2.00 | $2.09 | $1.91 | $1.95 | 24.78K |
| Sep 21, 2026 | $2.05 | $2.05 | $1.89 | $1.93 | 62.92K |
| Sep 18, 2026 | $1.9699 | $2.20 | $1.9699 | $2.10 | 199.47K |
| Sep 17, 2026 | $1.96 | $2.05 | $1.96 | $1.96 | 4.93K |
| Sep 16, 2026 | $2.04 | $2.09 | $1.95 | $1.95 | 5.61K |
| Sep 15, 2026 | $2.0595 | $2.075 | $2.00 | $2.01 | 7.81K |
| Sep 14, 2026 | $2.1185 | $2.1185 | $2.06 | $2.06 | 5.27K |
| Sep 11, 2026 | $2.11 | $2.11 | $2.05 | $2.06 | 17.53K |
Latest HIND news
The latest Smart Investors Daily articles mentioning HIND.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HIND research
Overview
Company profile and research snapshot.
Company profile
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 3, 2026 | Chardan Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 11, 2026
Vyome Files For Orphan Drug Status For VT-1953, Its Lead Clinical Program
Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3MIndependent third-party assessment estimates a current VT-1953
Benzinga · Feb 4, 2026
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · Feb 2, 2026
Vyome Capitalizes VT-1953 Phase 3 Interim Results By Raising $5.29M Through Sale Of 1,089,045 Shares At $5.00
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
